Roche to buy U.S. biotech firm InterMune for $8.3 billion
August 25, 2014 at 04:31 AM EDT
LONDON/ZURICH (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the treatment of rare or incurable diseases.
